Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 67, Issue 5, pp 971–983 | Cite as

An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting

Mini Review

Abstract

Purpose

The standard therapy for newly diagnosed malignant gliomas comprises surgery, radiotherapy, and commonly temozolomide chemotherapy. For recurrent or progressive disease after temozolomide failure, there is no consensus and only limited options for chemotherapy.

Methods

We reviewed the English literature for phase II trials of therapies for recurrent malignant glioma conducted between January 2000 and September 2010. The search was supplemented by a review of articles published prior to 2000 on chemotherapy regimens that had shown activity on recurrent gliomas.

Results

To guide practice in the general oncology setting, an algorithm was constructed according to the activity of the reported chemotherapies at the time of writing. Some molecular studies performed on tumor tissue may help guide the selection of chemotherapy. Methylated MGMT in tumor tissue correlates with increased sensitivity to alkylating agents such as fotemustine or other nitrosoureas. Depending on MGMT status and bone marrow reserve, treatment with fotemustine, bevacizumab, bevacizumab with irinotecan, or cis-retinoic acid (cRA), might be of value.

Conclusion

Unfortunately, progress in the development of new and more effective chemotherapy agents has been very limited and leaves the clinician treating high-grade glioma patients at relapse with few good options. The suggested algorithm is our objective evaluation of the currently existing knowledge. Hopefully, the ongoing phase II and III trials will provide us the needed chemotherapy agents in the years to come.

Keywords

Glioma Glioblastoma Chemotherapy Temozolomide 

References

  1. 1.
    Levin VA (1999) Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: the past decade and where we are heading. Neuro Oncol 1(1):69–80PubMedGoogle Scholar
  2. 2.
    Alexiou GA, Goussia A, Kyritsis AP, Tsiouris S, Ntoulia A, Malamou-Mitsi V, Voulgaris S, Fotopoulos AD (2010, Jun 15) Influence of Glioma’s Multidrug Resistance Phenotype on (99 m)Tc-Tetrofosmin Uptake. Mol Imaging Biol. [Epub ahead of print] doi: 10.1007/s11307-010-0369-y
  3. 3.
    Kyritsis AP, Zhang B, Zhang W, Xiao M, Takeshima H, Bondy ML, Cunningham JE, Levin VA, Bruner J (1996) Mutations of the p16 gene in gliomas. Oncogene 12(1):63–67PubMedGoogle Scholar
  4. 4.
    Gousias K, Markou M, Arzoglou V, Voulgaris S, Vartholomatos G, Kostoula A, Voulgari P, Polyzoidis K, Kyritsis AP (2010) Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy. J Neuroimmunol 226(1–2):136–142. doi: 10.1016/j.jneuroim.2010.05.027 PubMedCrossRefGoogle Scholar
  5. 5.
    Hadjipanayis CG, Van Meir EG (2009) Tumor initiating cells in malignant gliomas: biology and implications for therapy. J Mol Med 87(4):363–374. doi: 10.1007/s00109-009-0440-9 PubMedCrossRefGoogle Scholar
  6. 6.
    Kargiotis O, Geka A, Rao JS, Kyritsis AP (2010) Effects of irradiation on tumor cell survival, invasion and angiogenesis. J Neurooncol 100(3):323–338. doi: 10.1007/s11060-010-0199-4 PubMedCrossRefGoogle Scholar
  7. 7.
    Yung WK (2000) Temozolomide in malignant gliomas. Semin Oncol 27(3 Suppl 6):27–34Google Scholar
  8. 8.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi: 10.1056/NEJMoa043330 PubMedCrossRefGoogle Scholar
  9. 9.
    Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466. doi: 10.1016/S1470-2045(09)70025-7 PubMedCrossRefGoogle Scholar
  10. 10.
    Alexiou GA, Tsiouris S, Kyritsis AP, Voulgaris S, Argyropoulou MI, Fotopoulos AD (2009) Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities. J Neurooncol 95(1):1–11. doi: 10.1007/s11060-009-9897-1 PubMedCrossRefGoogle Scholar
  11. 11.
    Alexiou GA, Fotopoulos AD, Papadopoulos A, Kyritsis AP, Polyzoidis KS, Tsiouris S (2007) Evaluation of brain tumor recurrence by (99 m)Tc-tetrofosmin SPECT: a prospective pilot study. Ann Nucl Med 21(5):293–298. doi: 10.1007/s12149-007-0027-x PubMedCrossRefGoogle Scholar
  12. 12.
    Kaplan WD, Takvorian T, Morris JH, Rumbaugh CL, Connolly BT, Atkins HL (1987) Thallium-201 brain tumor imaging: a comparative study with pathologic correlation. J Nucl Med 28(1):47–52PubMedGoogle Scholar
  13. 13.
    Kumar AJ, Leeds NE, Fuller GN, Van Tassel P, Maor MH, Sawaya RE, Levin VA (2000) Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217(2):377–384PubMedGoogle Scholar
  14. 14.
    Wong ET, Jackson EF, Hess KR, Schomer DF, Hazle JD, Kyritsis AP, Jaeckle KA, Yung WK, Levin VA, Leeds NE (1998) Correlation between dynamic MRI and outcome in patients with malignant gliomas. Neurology 50(3):777–781PubMedGoogle Scholar
  15. 15.
    Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5):588–593. doi: 10.1054/bjoc.2000.1316S0007092000913168 Google Scholar
  16. 16.
    Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O’Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17(9):2762–2771Google Scholar
  17. 17.
    Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, Biscuola M, Blatt V, Crino L, Ermani M (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from Gruppo Italiano Cooperativo di Neuro-oncologia (GICNO). Br J Cancer 95(9):1155–1160. doi: 10.1038/sj.bjc.6603376 PubMedCrossRefGoogle Scholar
  18. 18.
    Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE (2005) Salvage temozolomide for prior temozolomide responders. Cancer 104(11):2473–2476. doi: 10.1002/cncr.21564 PubMedCrossRefGoogle Scholar
  19. 19.
    Wick W, Platten M, Weller M (2009) New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol 11(1):69–79. doi: 10.1215/15228517-2008-078 PubMedCrossRefGoogle Scholar
  20. 20.
    Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28(12):2051–2057. doi: 10.1200/JCO.2009.26.5520 PubMedCrossRefGoogle Scholar
  21. 21.
    Hess KR, Wong ET, Jaeckle KA, Kyritsis AP, Levin VA, Prados MD, Yung WK (1999) Response and progression in recurrent malignant glioma. Neuro Oncol 1(4):282–288PubMedGoogle Scholar
  22. 22.
    Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8):2572–2578PubMedGoogle Scholar
  23. 23.
    Levin VA, Ictech S, Hess KR (2007) Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer 7:106. doi: 10.1186/1471-2407-7-106 PubMedCrossRefGoogle Scholar
  24. 24.
    Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, Jaeckle KA (2007) The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 9(1):29–38. doi: 10.1215/15228517-2006-025 PubMedCrossRefGoogle Scholar
  25. 25.
    Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10(2):162–170. doi: 10.1215/15228517-2007-062 PubMedCrossRefGoogle Scholar
  26. 26.
    van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM (2009) End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald’s Criteria. J Clin Oncol 27(18):2905–2908. doi: 10.1200/JCO.2009.22.4998 PubMedCrossRefGoogle Scholar
  27. 27.
    Vos MJ, Uitdehaag BM, Barkhof F, Heimans JJ, Baayen HC, Boogerd W, Castelijns JA, Elkhuizen PH, Postma TJ (2003) Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology 60(5):826–830PubMedGoogle Scholar
  28. 28.
    Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS (2010) Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13:143–151. doi: 10.1093/neuonc/noq151 PubMedCrossRefGoogle Scholar
  29. 29.
    Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745. doi: 10.1200/JCO.2008.16.3055 PubMedCrossRefGoogle Scholar
  30. 30.
    Omuro AM (2008) Exploring multi-targeting strategies for the treatment of gliomas. Curr Opin Investig Drugs 9(12):1287–1295PubMedGoogle Scholar
  31. 31.
    Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA (2007) Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 83(1):53–60. doi: 10.1007/s11060-006-9302-2 PubMedCrossRefGoogle Scholar
  32. 32.
    Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A, Grosso D, Scopece L, Blatt V, Urbini B, Pession A, Tallini G, Crino L, Brandes AA (2007) Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 96(7):1047–1051. doi: 10.1038/sj.bjc.6603669 PubMedCrossRefGoogle Scholar
  33. 33.
    Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon JE, 2nd, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, Lyons P, Tourt-Uhlig S, Bigner DD, Friedman HS, Rich JN (2006) Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 12(3 Pt 1):860–868. doi: 10.1158/1078-0432.CCR-05-2215 Google Scholar
  34. 34.
    Neyns B, Sadones J, Joosens E, Bouttens F, Verbeke L, Baurain JF, D’Hondt L, Strauven T, Chaskis C, In’t Veld P, Michotte A, De Greve J (2009) Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 20(9):1596–1603. doi: 10.1093/annonc/mdp032 PubMedCrossRefGoogle Scholar
  35. 35.
    Brandes AA, Franceschi E, Tosoni A, Hegi ME, Stupp R (2008) Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin Cancer Res 14(4):957–960. doi: 10.1158/1078-0432.CCR-07-1810 PubMedCrossRefGoogle Scholar
  36. 36.
    Kargiotis O, Rao JS, Kyritsis AP (2006) Mechanisms of angiogenesis in gliomas. J Neurooncol 78(3):281–293. doi: 10.1007/s11060-005-9097-6 PubMedCrossRefGoogle Scholar
  37. 37.
    Chamberlain MC, Raizer J (2009) Antiangiogenic therapy for high-grade gliomas. CNS Neurol Disord Drug Targets 8(3):184–194PubMedGoogle Scholar
  38. 38.
    Norden AD, Drappatz J, Ciampa AS, Doherty L, LaFrankie DC, Kesari S, Wen PY (2009) Colon perforation during antiangiogenic therapy for malignant glioma. Neuro Oncol 11(1):92–95. doi: 10.1215/15228517-2008-071 PubMedCrossRefGoogle Scholar
  39. 39.
    Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70(10):779–787. doi: 10.1212/01.wnl.0000304121.57857.38 PubMedCrossRefGoogle Scholar
  40. 40.
    Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, Phan P, Ross A, Kesari S, Wen PY (2009) An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 92(2):149–155. doi: 10.1007/s11060-008-9745-8 PubMedCrossRefGoogle Scholar
  41. 41.
    Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, Zagzag D, Fischer I, Raza S, Medabalmi P, Eagan P, Gruber ML (2009) Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 110(1):173–180. doi: 10.3171/2008.4.17492 PubMedCrossRefGoogle Scholar
  42. 42.
    Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D, Ciampa A, Kesari S, Wen PY (2009) Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 11(5):550–555. doi: 10.1215/15228517-2009-006 PubMedCrossRefGoogle Scholar
  43. 43.
    Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS (2009) Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol 11(1):80–91. doi: 10.1215/15228517-2008-075 PubMedCrossRefGoogle Scholar
  44. 44.
    Gilbert MR, Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, Grossman S (2003) Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 9(8):2940–2949PubMedGoogle Scholar
  45. 45.
    Cloughesy TF, Filka E, Kuhn J, Nelson G, Kabbinavar F, Friedman H, Miller LL, Elfring GL (2003) Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 97(9 Suppl):2381–2386. doi: 10.1002/cncr.11306 PubMedCrossRefGoogle Scholar
  46. 46.
    Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J (2006) A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 8(2):189–193. doi: 10.1215/15228517-2005-010 PubMedCrossRefGoogle Scholar
  47. 47.
    Morabito A, Fanelli M, Carillio G, Gattuso D, Sarmiento R, Gasparini G (2004) Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. Oncol Rep 11(1):93–95PubMedGoogle Scholar
  48. 48.
    Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18(4):708–715PubMedGoogle Scholar
  49. 49.
    Fabi A, Metro G, Russillo M, Vidiri A, Carapella CM, Maschio M, Cognetti F, Jandolo B, Mirri MA, Sperduti I, Telera S, Carosi M, Pace A (2009) Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation. BMC Cancer 9:101. doi: 10.1186/1471-2407-9-101 PubMedCrossRefGoogle Scholar
  50. 50.
    Fabrini MG, Silvano G, Lolli I, Perrone F, Marsella A, Scotti V, Cionini L (2009) A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol 92(1):79–86. doi: 10.1007/s11060-008-9739-6 PubMedCrossRefGoogle Scholar
  51. 51.
    Scoccianti S, Detti B, Sardaro A, Iannalfi A, Meattini I, Leonulli BG, Borghesi S, Martinelli F, Bordi L, Ammannati F, Biti G (2008) Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs 19(6):613–620. doi: 10.1097/CAD.0b013e328300507500001813-200807000-00008 PubMedCrossRefGoogle Scholar
  52. 52.
    Wismeth C, Hau P, Fabel K, Baumgart U, Hirschmann B, Koch H, Jauch T, Grauer O, Drechsel L, Brawanski A, Bogdahn U, Steinbrecher A (2004) Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy–a phase-II study. J Neurooncol 68(1):79–86PubMedCrossRefGoogle Scholar
  53. 53.
    Yung WK, Kyritsis AP, Gleason MJ, Levin VA (1996) Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res 2(12):1931–1935PubMedGoogle Scholar
  54. 54.
    See SJ, Levin VA, Yung WK, Hess KR, Groves MD (2004) 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro Oncol 6(3):253–258. doi: 10.1215/S1152851703000607 PubMedCrossRefGoogle Scholar
  55. 55.
    Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M (2004) Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol 22(21):4282–4289. doi: 10.1200/JCO.2004.09.096 PubMedCrossRefGoogle Scholar
  56. 56.
    Kaba SE, Kyritsis AP, Conrad C, Gleason MJ, Newman R, Levin VA, Yung WK (1997) The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin). J Neurooncol 34(2):145–151PubMedCrossRefGoogle Scholar
  57. 57.
    Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ (2008) Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 14(21):7068–7073. doi: 10.1158/1078-0432.CCR-08-0260 PubMedCrossRefGoogle Scholar
  58. 58.
    Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729. doi: 10.1200/JCO.2007.12.2440 PubMedCrossRefGoogle Scholar
  59. 59.
    Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740. doi: 10.1200/JCO.2008.19.8721 PubMedCrossRefGoogle Scholar
  60. 60.
    Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253–1259. doi: 10.1158/1078-0432.CCR-06-2309 PubMedCrossRefGoogle Scholar
  61. 61.
    Kang TY, Jin T, Elinzano H, Peereboom D (2008) Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J Neurooncol 89(1):113–118. doi: 10.1007/s11060-008-9599-0 PubMedCrossRefGoogle Scholar
  62. 62.
    Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, Kosteljanetz M, Lassen U (2009) Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol 48(1):52–58. doi: 10.1080/02841860802537924 PubMedCrossRefGoogle Scholar
  63. 63.
    Bokstein F, Shpigel S, Blumenthal DT (2008) Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112(10):2267–2273. doi: 10.1002/cncr.23401 PubMedCrossRefGoogle Scholar
  64. 64.
    Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H, de Groot JF, Ritterhouse MG, Ictech SE, Yung WK (2008) Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol 10(2):216–222. doi: 10.1215/15228517-2007-060 PubMedCrossRefGoogle Scholar
  65. 65.
    Fadul CE, Kingman LS, Meyer LP, Cole BF, Eskey CJ, Rhodes CH, Roberts DW, Newton HB, Pipas JM (2008) A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. J Neurooncol 90(2):229–235. doi: 10.1007/s11060-008-9655-9 PubMedCrossRefGoogle Scholar
  66. 66.
    Feun LG, Marini A, Landy H, Markoe A, Heros D, Robles C, Herrera C, Savaraj N (2007) Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors. J Neurooncol 82(2):177–181. doi: 10.1007/s11060-006-9261-7 PubMedCrossRefGoogle Scholar
  67. 67.
    Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Vredenburgh J, Gururangan S, Provenzale JM, Walker A, Schweitzer H, Bigner DD, Tourt-Uhlig S, Herndon JE 2nd, Affronti ML, Jackson S, Allen D, Ziegler K, Bohlin C, Lentz C, Friedman HS (2004) Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro Oncol 6(2):145–153. doi: 10.1215/S1152851703000498 PubMedCrossRefGoogle Scholar
  68. 68.
    Reardon DA, Quinn JA, Rich JN, Gururangan S, Vredenburgh J, Sampson JH, Provenzale JM, Walker A, Badruddoja M, Tourt-Uhlig S, Herndon JE 2nd, Dowell JM, Affronti ML, Jackson S, Allen D, Ziegler K, Silverman S, Bohlin C, Friedman AH, Bigner DD, Friedman HS (2004) Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol 6(2):134–144PubMedCrossRefGoogle Scholar
  69. 69.
    Happold C, Roth P, Wick W, Steinbach JP, Linnebank M, Weller M, Eisele G (2009) ACNU-based chemotherapy for recurrent glioma in the temozolomide era. J Neurooncol 92(1):45–48. doi: 10.1007/s11060-008-9728-9 PubMedCrossRefGoogle Scholar
  70. 70.
    Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE 2nd, Dowell JM, Friedman AH, Friedman HS (2005) Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 103(2):329–338. doi: 10.1002/cncr.20776 PubMedCrossRefGoogle Scholar
  71. 71.
    Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE 2nd, Marcello JE, Norfleet J, Friedman AH, Bigner DD, Friedman HS (2009) Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 101(12):1986–1994. doi: 10.1038/sj.bjc.6605412 PubMedCrossRefGoogle Scholar
  72. 72.
    Tang P, Roldan G, Brasher PM, Fulton D, Roa W, Murtha A, Cairncross JG, Forsyth PA (2006) A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neurooncol 78(3):311–316. doi: 10.1007/s11060-005-9104-y PubMedCrossRefGoogle Scholar
  73. 73.
    Hau P, Fabel K, Baumgart U, Rummele P, Grauer O, Bock A, Dietmaier C, Dietmaier W, Dietrich J, Dudel C, Hubner F, Jauch T, Drechsel E, Kleiter I, Wismeth C, Zellner A, Brawanski A, Steinbrecher A, Marienhagen J, Bogdahn U (2004) Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 100(6):1199–1207. doi: 10.1002/cncr.20073 PubMedCrossRefGoogle Scholar
  74. 74.
    de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK (2008) Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol 90(1):89–97. doi: 10.1007/s11060-008-9637-y PubMedCrossRefGoogle Scholar
  75. 75.
    Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28(7):1168–1174. doi: 10.1200/JCO.2009.23.2595
  76. 76.
    Ahluwalia MS (2010) Society for Neuro-Oncology Annual Meeting: a report of selected studies. Expert Rev Anticancer Ther 11(2):161–163. doi: 10.1586/era.10.227 CrossRefGoogle Scholar
  77. 77.
    Kyritsis AP, Yung WK, Jaeckle KA, Bruner J, Gleason MJ, Ictech SE, Flowers A, Levin VA (1996) Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. Neurosurgery 39(5):921–926PubMedGoogle Scholar
  78. 78.
    Walbert T, Gilbert MR, Groves MD, Puduvalli VK, Alfred Yung WK, Conrad CA, Bobustuc GC, Colman H, Hsu SH, Nebiyou Bekele B, Qiao W, Levin VA (2010) Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. J Neurooncol. doi: 10.1007/s11060-010-0313-7
  79. 79.
    Silber JR, Blank A, Bobola MS, Ghatan S, Kolstoe DD, Berger MS (1999) O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 5(4):807–814PubMedGoogle Scholar
  80. 80.
    Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003. doi: 10.1056/NEJMoa043331 PubMedCrossRefGoogle Scholar
  81. 81.
    Bobustuc GC, Baker CH, Limaye A, Jenkins WD, Pearl G, Avgeropoulos NG, Konduri SD (2010) Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol 12(9):917–927. doi: 10.1093/neuonc/noq044 PubMedCrossRefGoogle Scholar
  82. 82.
    Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, Provenzale JM, Gururangan S, Dancey JE, Maxwell J, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS (2005) Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 23(28):7178–7187. doi: 10.1200/JCO.2005.06.502 PubMedCrossRefGoogle Scholar
  83. 83.
    Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE 2nd, Walker A, Friedman HS (2009) Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 27(8):1262–1267. doi: 10.1200/JCO.2008.18.8417 PubMedCrossRefGoogle Scholar
  84. 84.
    Walker C, Haylock B, Husband D, Joyce KA, Fildes D, Jenkinson MD, Smith T, Broome J, du Plessis DG, Warnke PC (2006) Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology 66(11):1661–1667. doi: 10.1212/01.wnl.0000218270.12495.9a PubMedCrossRefGoogle Scholar
  85. 85.
    Snuderl M, Eichler AF, Ligon KL, Vu QU, Silver M, Betensky RA, Ligon AH, Wen PY, Louis DN, Iafrate AJ (2009) Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res 15(20):6430–6437. doi: 10.1158/1078-0432.CCR-09-0867 PubMedCrossRefGoogle Scholar
  86. 86.
    Chamberlain MC, Glantz MJ (2008) CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. J Neurooncol 89(2):231–238. doi: 10.1007/s11060-008-9613-6 PubMedCrossRefGoogle Scholar
  87. 87.
    Taillibert S, Vincent LA, Granger B, Marie Y, Carpentier C, Guillevin R, Bellanger A, Mokhtari K, Rousseau A, Psimaras D, Dehais C, Sierra del Rio M, Meng Y, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY (2009) Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology 72(18):1601–1606. doi: 10.1212/WNL.0b013e3181a413be PubMedCrossRefGoogle Scholar
  88. 88.
    Chamberlain MC, Johnston S (2009) Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer 115(8):1734–1743. doi: 10.1002/cncr.24179 PubMedCrossRefGoogle Scholar
  89. 89.
    Kyritsis AP, Bondy ML, Levin VA (2011) Modulation of Glioma Risk and Progression by Dietary Nutrients and Antiinflammatory Agents. Nutr Cancer 63(2):174–184 doi: 10.1080/01635581.2011.523807 Google Scholar
  90. 90.
    Bakshi A, Mukherjee D, Banerji AK, Das UN (2003) Gamma-linolenic acid therapy of human gliomas. Nutrition 19(4):305–309. doi: S0899900702008626 PubMedCrossRefGoogle Scholar
  91. 91.
    Levin VA, Chamberlain MC, Prados MD, Choucair AK, Berger MS, Silver P, Seager M, Gutin PH, Davis RL, Wilson CB (1987) Phase I–II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors. Cancer Treat Rep 71(5):459–464PubMedGoogle Scholar
  92. 92.
    Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, Gleason MJ, Kim HW (2003) Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9(3):981–990PubMedGoogle Scholar
  93. 93.
    Levin VA, Uhm JH, Jaeckle KA, Choucair A, Flynn PJ, Yung WKA, Prados MD, Bruner JM, Chang SM, Kyritsis AP, Gleason MJ, Hess KR (2000) Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N’-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res 6(10):3878–3884PubMedGoogle Scholar
  94. 94.
    Kargiotis O, Markoula S, Kyritsis AP (2011) Epilepsy in the cancer patient. Cancer Chemother Pharmacol 67(3):489–501. doi: 10.1007/s00280-011-1569-0 PubMedCrossRefGoogle Scholar
  95. 95.
    Wheeler CJ (2010) Dendritic cell vaccines to combat glioblastoma. Expert Rev Neurother 10(4):483–486. doi: 10.1586/ern.10.26 PubMedCrossRefGoogle Scholar
  96. 96.
    Kyritsis AP, Sioka C, Rao JS (2009) Viruses, gene therapy and stem cells for the treatment of human glioma. Cancer Gene Ther 16(10):741–752. doi: 10.1038/cgt.2009.52 PubMedCrossRefGoogle Scholar
  97. 97.
    Kargiotis O, Chetty C, Gondi CS, Tsung AJ, Dinh DH, Gujrati M, Lakka SS, Kyritsis AP, Rao JS (2008) Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma. Oncogene 27(35):4830–4840. doi: 10.1038/onc.2008.122 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Neurosurgical Research InstituteUniversity of IoanninaIoanninaGreece
  2. 2.Department of NeurologyUniversity of Ioannina School of MedicineIoanninaGreece
  3. 3.Department of Neuro-OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  4. 4.Kaiser PermanenteRedwood CityUSA

Personalised recommendations